HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO): The first patient has now been included in Karo Bio's phase III trial (the AKKA study) with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.
